VEGFA and COVID-19: A humanized monoclonal antibody against VEGF, Bevacizumab plus standard care can be very beneficial for patients with severe COVID-19.450 The lung function of COVID-19 patients improved significantly after FX06 administration, which may be attributed to its immunomodulatory properties and its ability to protect the endothelial barrier and reduce vascular hypertonicity.451